Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03850964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorPrimary completion date changed from estimate of Nov 2025 to Nov 21, 2025
Publications: details revised at 1 of 3 entries
v18
MinorTrial status: Recruiting to Active, Not Recruitingv17Show 4 more changesShow less
Study sites: 12 to 11
Primary completion date: Sep 30, 2025 to Nov 2025
Study completion date: Oct 1, 2026 to Jul 2026
Publications: details revised at 1 of 3 entries
MinorPrimary completion date: Jul 31, 2025 to Sep 30, 2025
Study completion date: Mar 31, 2026 to Oct 1, 2026
Site details revised at 2 of 12 sites
v16
MinorStudy sites: 10 to 12v15
MinorStudy sites: 11 to 10
Publications: details revised at 1 of 3 entries
v14
Show 12 earlier versionsHide 12 earlier versions
MinorSite contacts updated at 11 of 11 sites
Publications: details revised at 1 of 3 entries
v13
MinorEligibility criteria expanded, about 7 wordsv12
MinorStudy sites: 10 to 11
Eligibility criteria expanded, about 19 words
v11
MinorStudy sites: 7 to 10v10
MinorStudy sites: 5 to 7v9
MinorStudy sites: 2 to 5
Secondary endpoints: 13 to 5
v8
MinorStudy sites: 1 to 2
Eligibility criteria expanded, about 28 words
Collaborators shortened, about 10 words
Study arms: 4 to 5
v7
MinorStart date changed from estimate of May 1, 2023 to May 8, 2023
Eligibility criteria shortened, about 8 words
v6
NotableTrial status: Not Yet Recruiting to Recruitingv5Show 7 more changesShow less
Primary completion date: Nov 30, 2024 to Jul 31, 2025
Start date: Dec 1, 2022 to May 1, 2023
Study sites: 0 to 1
Study completion date: Jun 30, 2025 to Mar 31, 2026
Eligibility criteria expanded, about 242 words
Collaborators: 1 to 2
Publications: 2 to 3
NotableStart date: Oct 1, 2022 to Dec 1, 2022v4Show 6 more changesShow less
Primary completion date: Sep 30, 2024 to Nov 30, 2024
Eligibility criteria expanded, about 63 words
Secondary endpoints: details revised at 1 of 13 entries
Study arms: 5 to 4
Study description expanded, about 2 words
Study title expanded, about 5 words
MinorStudy title shortened, about 1 wordv3
NotableEnrollment target: 45 to 70v2Show 9 more changesShow less
Primary completion date: Dec 2020 to Sep 30, 2024
Start date: Sep 2019 to Oct 1, 2022
Primary endpoints: 1 to 2
Study completion date: Mar 2021 to Jun 30, 2025
Eligibility criteria expanded, about 292 words
Secondary endpoints revised (13)
Study description expanded, about 106 words
Study arms: 2 to 5
Collaborators expanded, about 5 words
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.